GBS Inc. (GBS)
After hours:
| Previous close | 0.7900 |
| Open | 0.8105 |
| Bid | 0.7201 x 1100 |
| Ask | 0.7900 x 1000 |
| Day's range | 0.7392 - 0.8194 |
| 52-week range | 0.3810 - 5.1100 |
| Volume | |
| Avg. volume | 649,783 |
| Market cap | 11.007M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5020 |
| Earnings date | 11 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
- GlobeNewswire
GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Australia have selected a site for its proprietary biosensor technology. “Maintaining momentum with our partners at the University of Newcastle has been and will remain a principal objective to generating shareholder
- GlobeNewswire
GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022
NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care (the “Company”), today announced that the Company has adjourned its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) originally scheduled to be held on June 16, 2022, to July 13, 2022, at 4:00 p.m., Eastern Time, or at such other time or such other date to which the meeting
- GlobeNewswire
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse
- Intelligent Fingerprinting Limited’s commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipelineNEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has executed an exclusivity agreement with Intelligent Fingerprinting Limited (“IF
